全文获取类型
收费全文 | 75672篇 |
免费 | 5041篇 |
国内免费 | 2720篇 |
出版年
2023年 | 1197篇 |
2022年 | 1115篇 |
2021年 | 2432篇 |
2020年 | 2477篇 |
2019年 | 3439篇 |
2018年 | 2978篇 |
2017年 | 2144篇 |
2016年 | 2109篇 |
2015年 | 2565篇 |
2014年 | 4983篇 |
2013年 | 6559篇 |
2012年 | 3805篇 |
2011年 | 4950篇 |
2010年 | 3732篇 |
2009年 | 4053篇 |
2008年 | 4086篇 |
2007年 | 4119篇 |
2006年 | 3703篇 |
2005年 | 3217篇 |
2004年 | 2841篇 |
2003年 | 2259篇 |
2002年 | 2037篇 |
2001年 | 1236篇 |
2000年 | 967篇 |
1999年 | 982篇 |
1998年 | 865篇 |
1997年 | 651篇 |
1996年 | 597篇 |
1995年 | 614篇 |
1994年 | 573篇 |
1993年 | 439篇 |
1992年 | 435篇 |
1991年 | 367篇 |
1990年 | 296篇 |
1989年 | 246篇 |
1988年 | 214篇 |
1987年 | 187篇 |
1986年 | 164篇 |
1985年 | 346篇 |
1984年 | 571篇 |
1983年 | 413篇 |
1982年 | 436篇 |
1981年 | 352篇 |
1980年 | 278篇 |
1979年 | 244篇 |
1978年 | 222篇 |
1977年 | 200篇 |
1976年 | 167篇 |
1975年 | 159篇 |
1973年 | 152篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
Anti-TNF biologics have achieved great success in the treatment of autoimmune diseases and have been the most selling biologics on market. However, the anti-TNF biologics have shown some disadvantages such as poor efficacy to some patients and high risk of infection and malignancies during clinical application. Current anti-TNF biologics are antibodies or antibody fragments that bind to TNF-α and subsequently block both TNF-TNFR1 and TNF-TNFR2 signaling. Transgenic animal studies indicate that TNFR1 signaling is responsible for chronic inflammation and cell apoptosis whereas TNFR2 signaling regulates tissue regeneration and inflammation. Recent studies propose to selectively inhibit TNFR1 to enhance efficacy and avoid side effects. In this review, we introduce the biology of TNF-TNFR1 and TNF-TNFR2 signaling, the advantages of selective inhibition of TNF-TNFR1 signaling and research updates on the development of selective inhibitors for TNF-TNFR1 signaling. Antibodies, small molecules and aptamers that selectively inhibit TNFR1 have showed therapeutic potential and less side effects in preclinical studies. Development of selective inhibitors for TNFR1 is a good strategy to enhance the efficacy and reduce the side effects of anti-TNF inhibitors and will be a trend for next-generation of anti-TNF inhibitors. 相似文献
103.
104.
《Current biology : CB》2020,30(24):4826-4836.e7
105.
Origin of bombesin-like peptides in human fetal lung 总被引:2,自引:0,他引:2
Four different forms of bombesin-like immunoreactive peaks were detected in extracts of human fetal lung by the use of reversed-phase high performance liquid chromatography (HPLC). Peaks I, II, III and IV, (increasing retention time), were eluted using a 14-38% of acetonitrile gradient containing 0.1% trifluoroacetic acid (TFA). Peak II was the major material found in the extract of human fetal lung obtained at 16-20 weeks gestation. None of the four compounds contained in the eluted peaks had the same retention time as amphibian bombesin or porcine gastrin releasing peptide (GRP). On reversed-phase HPLC using two different solvent systems TFA or heptafluorobutyric acid (HFBA) as a hydrophobic counter ion, and in gel filtration chromatography, the chromatographic behavior of the main peak (peak II) was the same as that of the carboxyl terminal fragments of GRP, GRP18-27 or GRP19-27. This suggested that the peptide(s) in peak II resembled in composition the carboxy terminal 9 or 10 amino acids of porcine GRP. Following tryptic digestion the material in peak IV was converted to the more polar compound present in peak II. Two other peptide peaks were eluted close to peak II and these were presumed to be a modification of this main peak. One of the possible biosynthetic steps in the formation of bombesin-like peptides in human fetal lung could be a tryptic conversion of a less polar peptide to a more polar form (peak IV to II). 相似文献
106.
Peter J. Meloncelli 《Carbohydrate research》2010,345(16):2305-2322
The ABO histo-blood group system is one of the most clinically important antigen families. As part of our overall goal to prepare the entire set of the A, B and H type I-VI antigens for a range of biochemical investigations, we report herein the synthesis of the type I and II antigens with a 7-octen-1-yl aglycone. This linker was chosen to facilitate not only the future conjugation of the antigens to a protein or solid support but also the synthesis of the H type I and II octyl glycosides for enzyme kinetic studies. 相似文献
107.
108.
109.
《Molecular cell》2020,77(2):228-240.e7
110.
《Molecular cell》2020,77(4):748-760.e9